EL PHARMA (Evropa Lek Pharma) has been a member of the PHOENIX group since 2009, established with the aim of providing additional services in the pharmaceutical sector.
As a full-service provider, we provide our partners with support for the entire CEE (Central East Europe) region, starting from the process of drug or medical device registration, throug import and distribution, launch, positioning. We provide our partners with complete safety in the whole process thanks to the high standards defined by strict procedures in the areas of compliance and quality.
Our team is professional and highly motivated to offer tailor-made services, according to individual needs of our pharmaceutical partners. If you need a reliable partner as support to market access, medical affairs, registration of drugs and medical devices, or marketing and sales support we believe that we can be your first choice partner. We can offer even more. We also can be a one point contact for warehouse services in bonded warehouse, clinical trials logistic or additional value added services in our warehouse.
Significant changes taking place in the pharmaceutical market greatly affect the operations of pharmaceutical companies. A large number of services we provide to our partners provide more efficient market entry and the opportunity to improve business parameters through increased sales, cost reduction and business optimization.
Organization of business in accordance with the latest world trends and the requirements of good practices, constant listening to market demands, modern working conditions and new technological solutions, allow us to be recognized in the market by the specific services we offer.
EL PHARMA Serbia is part of the West Balkan Group, connected with its branches in Bosnia and Herzegovina, North Macedonia, Montenegro, as well as with the PHOENIX CEE network, which enables our partners to access the markets of the entire region.
If you think we can become partners, get acquainted with our way of working through this site and contact us.